Placebo for BI 655130 (solution for injection)

DRUG2 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim RCV GmbH & Co. KG

Conditions

Hidradenitis suppurativaNetherton syndrome (NS)

Phase 2

Evasayil TM: A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome

CompletedCTIS2022-501104-10-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim RCV GmbH & Co. KGNetherton syndrome (NS)

Start: 2023-06-06End: 2025-07-31Target: 20Updated: 2025-06-16

Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.

CompletedCTIS2022-501074-19-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim RCV GmbH & Co. KGHidradenitis suppurativa

Start: 2023-10-13End: 2025-03-31Target: 89Updated: 2025-05-13